| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Innate Pharma (NASDAQ:IPHA) with a Buy and maintains $11.5...
Cash position of €102.1 million2 as of June 30, 2024, anticipated cash runway to end of 2025
The preliminary data of three arms were presented at WCLC, namely: Arm 1: oleclumab in combination with durvalumab and plati...
SAR443579/IPH6101, ANKET® platform lead asset, is a first-in-class NKp46/CD16-based NK cell engager targeting CD123 from a jo...
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Innate Pharma (NASDAQ:IPHA) with a Buy and maintains $11.5...
In heavily pretreated patients with mycosis fungoides, treatment with lacutamab results in meaningful anti-tumor activity reg...
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Innate Pharma (NASDAQ:IPHA) with a Buy and maintains $11.5...
Two abstracts on SAR443579 (IPH6101), ANKET® platform lead asset, a trifunctional anti-CD123 NKp46xCD16 NK cell engager under...
First preclinical data set for IPH45, a pre-IND anti-Nectin-4 Antibody Drug Conjugate, presented as an oral presentation at A...
